Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
|
$876.40B |
$927.04
+2.55%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$564.21B |
$234.19
-0.15%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$368.29B |
$208.44
-0.26%
|
|
AZN
AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
|
$317.44B |
$204.81
+2.16%
|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$295.53B |
$119.10
+3.15%
|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides companion diagnostics (e.g., Oncomine Dx tests) that inform targeted therapies.
|
$197.85B |
$526.48
+2.03%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$191.32B |
$355.23
+1.67%
|
|
NVO
Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
|
$180.05B |
$40.51
-1.04%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
|
$170.77B |
$137.61
-0.68%
|
|
ABT
Abbott Laboratories
Abbott competes in generic drug segments across emerging markets, aligning with the Generic Drugs theme within Established Pharmaceutical Products.
|
$168.34B |
$96.86
+1.46%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$156.70B |
$27.56
+1.25%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$122.49B |
$60.17
+2.06%
|
Showing page 1 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
